Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Organogenesis Holdings Inc.ORGO · Entity 6275 | Director · President and CEO | February 18, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Organogenesis Holdings Inc.
Report date February 18, 2026 · Filed March 03, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 4,232,087 |
Last balance in matching sequence
After 2026-02-18 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-02-18 · Grant · Acquired 188,856 · Balance 4,323,398 F1: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Row 2 · 2026-02-18 · Tax withholding · Disposed 91,311 · Balance 4,232,087 F1: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2026 Filed Feb 20, 2026 22:27 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 507,795 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0002064832-26-000057 · form4.xml · derivative · entry 4 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 507,795 Underlying: Class A Common Stock · 507,795 shares Expires 2036-02-18 F3 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2026. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:27 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 90,398 | $3.84 | $347,128.32 |
DisclosureSEC source: 0002064832-26-000057 · form4.xml · nonDerivative · entry 3 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,231,112 Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:27 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 186,968 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000057 · form4.xml · nonDerivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,321,510 F2 · shares: Shares issued pursuant to the vesting and settlement of a performance share award granted in 2025 based on the achievement of certain performance milestones. Read SEC document |
| February 18, 2026 Filed Feb 20, 2026 22:27 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 890,625 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000057 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,134,542 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2026. Read SEC document |
| February 18, 2026 Filed Mar 3, 2026 21:35 UTC Amendment | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 91,311 | $3.84 | $350,634.24 |
DisclosureSEC source: 0002064832-26-000091 · form4a.xml · nonDerivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,232,087 F1 · shares: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Read SEC document |
| February 18, 2026 Filed Mar 3, 2026 21:35 UTC Amendment | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 188,856 | $0.00 | $0.00 |
DisclosureSEC source: 0002064832-26-000091 · form4a.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,323,398 F1 · shares: This Form 4 is being filed as an amendment to the Form 4 originally filed on February 20, 2026, to correct the number of shares reported as acquired upon the vesting and settlement of a performance share award and the number of shares reported as withheld in satisfaction of tax obligations in connection with such award. No other changes have been made to the original filing. Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:36 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 85,605 | $3.73 | $319,306.65 |
DisclosureSEC source: 0002064832-26-000027 · form4.xml · nonDerivative · entry 4 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,243,917 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:36 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 82,815 | $3.73 | $308,899.95 |
DisclosureSEC source: 0002064832-26-000027 · form4.xml · nonDerivative · entry 3 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,329,522 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:36 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 78,646 | $3.73 | $293,349.58 |
DisclosureSEC source: 0002064832-26-000027 · form4.xml · nonDerivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,412,337 Read SEC document |
| February 15, 2026 Filed Feb 18, 2026 21:36 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 24,340 | $3.73 | $90,788.20 |
DisclosureSEC source: 0002064832-26-000027 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,490,983 Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:42 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 732,596 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001062993-25-003212 · form4.xml · derivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 732,596 Underlying: Class A Common Stock · 732,596 shares Expires 2035-02-19 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2025. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:42 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 708,215 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-003212 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,515,323 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2025. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 00:19 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 6,123 | $3.70 | $22,655.10 |
DisclosureSEC source: 0001062993-25-002937 · form4.xml · nonDerivative · entry 4 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,807,108 Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 00:19 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 33,869 | $3.70 | $125,315.30 |
DisclosureSEC source: 0001062993-25-002937 · form4.xml · nonDerivative · entry 3 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,813,231 Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 00:19 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 109,280 | $3.70 | $404,336.00 |
DisclosureSEC source: 0001062993-25-002937 · form4.xml · nonDerivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,847,100 Read SEC document |
| February 15, 2025 Filed Feb 20, 2025 00:19 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 82,814 | $3.70 | $306,411.80 |
DisclosureSEC source: 0001062993-25-002937 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,956,380 Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 01:03 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 5,585 | $3.49 | $19,491.65 |
DisclosureSEC source: 0001062993-24-020701 · form4.xml · nonDerivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,039,194 F1 · shares: The reported disposition represents the sale of shares to cover the withholding tax that was previously paid to the issuer arising from the exercise of the expiring stock option reported on the Form 4 filed by the reporting person on December 9, 2024. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.36 to $3.5275, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| December 13, 2024 Filed Dec 17, 2024 01:03 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 55,615 | $3.36 | $186,866.40 |
DisclosureSEC source: 0001062993-24-020701 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,044,779 F1 · shares: The reported disposition represents the sale of shares to cover the withholding tax that was previously paid to the issuer arising from the exercise of the expiring stock option reported on the Form 4 filed by the reporting person on December 9, 2024. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.2806 to $3.50, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 01:08 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 43,359 | $3.55 | $153,924.45 |
DisclosureSEC source: 0001062993-24-020566 · form4.xml · nonDerivative · entry 3 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,100,394 F1 · shares: The reported disposition represents the sale of shares to cover the withholding tax that was previously paid to the issuer arising from the exercise of the expiring stock option reported on the Form 4 filed by the reporting person on December 9, 2024. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.495 to $3.65, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 01:08 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 157,448 | $3.64 | $573,110.72 |
DisclosureSEC source: 0001062993-24-020566 · form4.xml · nonDerivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,143,753 F1 · shares: The reported disposition represents the sale of shares to cover the withholding tax that was previously paid to the issuer arising from the exercise of the expiring stock option reported on the Form 4 filed by the reporting person on December 9, 2024. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.51 to $3.72, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| December 10, 2024 Filed Dec 13, 2024 01:08 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 58,525 | $3.64 | $213,031.00 |
DisclosureSEC source: 0001062993-24-020566 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,301,201 F1 · shares: The reported disposition represents the sale of shares to cover the withholding tax that was previously paid to the issuer arising from the exercise of the expiring stock option reported on the Form 4 filed by the reporting person on December 9, 2024. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.4531 to $3.74, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 01:05 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 41,052 | $3.52 | $144,503.04 |
DisclosureSEC source: 0001062993-24-020285 · form4.xml · nonDerivative · entry 3 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,359,726 F1 · shares: The reported disposition represents the sale of shares to cover the withholding tax that was previously paid to the issuer arising from the exercise of the expiring stock option reported above. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.48 to $3.69, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 01:05 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 18,416 | $3.65 | $67,218.40 |
DisclosureSEC source: 0001062993-24-020285 · form4.xml · nonDerivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,400,778 F1 · shares: The reported disposition represents the sale of shares to cover the withholding tax that was previously paid to the issuer arising from the exercise of the expiring stock option reported above. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.6132 to $3.6858, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| December 05, 2024 Filed Dec 10, 2024 01:05 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,067,245 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001062993-24-020285 · form4.xml · derivative · entry 4 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 1,067,245 shares Expires 2024-12-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| December 05, 2024 Filed Dec 10, 2024 01:05 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 1,067,245 | $0.99 | $1,056,572.55 |
DisclosureSEC source: 0001062993-24-020285 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,419,194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 20:22 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 10,113 | $2.80 | $28,316.40 |
DisclosureSEC source: 0001062993-24-007931 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,351,949 Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:23 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 1,238,729 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001062993-24-004310 · form4.xml · derivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,238,729 Underlying: Class A Common Stock · 1,238,729 shares Expires 2034-02-21 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2024. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 22:23 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 685,131 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-004310 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,362,062 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2024. Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 01:18 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 3,788 | $3.48 | $13,182.24 |
DisclosureSEC source: 0001062993-24-003764 · form4.xml · nonDerivative · entry 3 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,676,931 Read SEC document |
| February 15, 2024 Filed Feb 21, 2024 01:18 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 21,439 | $3.68 | $78,895.52 |
DisclosureSEC source: 0001062993-24-003764 · form4.xml · nonDerivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,680,719 Read SEC document |
| February 15, 2024 Filed Feb 21, 2024 01:18 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 65,774 | $3.68 | $242,048.32 |
DisclosureSEC source: 0001062993-24-003764 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,702,158 Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 20:20 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 6,470 | $2.13 | $13,781.10 |
DisclosureSEC source: 0001062993-23-008507 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,767,932 Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:49 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantStock Option (Right to Buy) · Derivative | 1,655,381 | $0.00 Strike: $2.51 | $0.00 |
DisclosureSEC source: 0001062993-23-004887 · form4.xml · derivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,655,381 Underlying: Class A Common Stock · 1,655,381 shares Expires 2033-02-22 F2 · derivative.exercise_date: The option becomes exercisable in equal annual installments over four years beginning February 15, 2023. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:49 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | GrantClass A Common Stock | 896,414 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-004887 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,774,402 F1 · kind: Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 15, 2023. Read SEC document |
| February 16, 2023 Filed Feb 17, 2023 21:23 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 3,787 | $2.75 | $10,414.25 |
DisclosureSEC source: 0001062993-23-004054 · form4.xml · nonDerivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 877,988 Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:23 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Tax withholdingClass A Common Stock | 21,517 | $2.92 | $62,829.64 |
DisclosureSEC source: 0001062993-23-004054 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 881,775 Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 21:03 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 505,050 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001062993-22-015767 · form4.xml · derivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 505,050 shares Expires 2023-07-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| June 30, 2022 Filed Jul 1, 2022 21:03 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 505,050 | $0.99 | $499,999.50 |
DisclosureSEC source: 0001062993-22-015767 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 903,292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 03, 2022 Filed Jun 3, 2022 20:51 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 36,239 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001062993-22-014294 · form4.xml · derivative · entry 9 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 36,239 shares Expires 2024-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| June 03, 2022 Filed Jun 3, 2022 20:51 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 36,239 | $5.53 | $200,401.67 |
DisclosureSEC source: 0001062993-22-014294 · form4.xml · nonDerivative · entry 6 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,242 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.44 to $5.62, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. Read SEC document |
| June 03, 2022 Filed Jun 3, 2022 20:51 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 36,239 | $0.99 | $35,876.61 |
DisclosureSEC source: 0001062993-22-014294 · form4.xml · nonDerivative · entry 5 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 434,481 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 20:51 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 116,608 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001062993-22-014294 · form4.xml · derivative · entry 8 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,239 Underlying: Class A Common Stock · 116,608 shares Expires 2024-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 20:51 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 116,608 | $5.58 | $650,672.64 |
DisclosureSEC source: 0001062993-22-014294 · form4.xml · nonDerivative · entry 4 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,242 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.44 to $5.73, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 20:51 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 116,608 | $0.99 | $115,441.92 |
DisclosureSEC source: 0001062993-22-014294 · form4.xml · nonDerivative · entry 3 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 514,850 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:51 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 94,487 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001062993-22-014294 · form4.xml · derivative · entry 7 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,847 Underlying: Class A Common Stock · 94,487 shares Expires 2024-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:51 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 94,487 | $5.52 | $521,568.24 |
DisclosureSEC source: 0001062993-22-014294 · form4.xml · nonDerivative · entry 2 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,242 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.45 to $5.66, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:51 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 94,487 | $0.99 | $93,542.13 |
DisclosureSEC source: 0001062993-22-014294 · form4.xml · nonDerivative · entry 1 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 492,729 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2022 Filed May 31, 2022 21:16 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionStock Option (Right to Buy) · Derivative | 109,240 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001062993-22-013879 · form4.xml · derivative · entry 9 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,334 Underlying: Class A Common Stock · 109,240 shares Expires 2024-08-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| May 31, 2022 Filed May 31, 2022 21:16 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | SaleClass A Common Stock | 109,240 | $5.68 | $620,483.20 |
DisclosureSEC source: 0001062993-22-013879 · form4.xml · nonDerivative · entry 6 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,242 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in March 2022. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $5.58 to $5.89, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. Read SEC document |
| May 31, 2022 Filed May 31, 2022 21:16 UTC | Organogenesis Holdings Inc. ORGO · Entity 6275 | Exercise / conversionClass A Common Stock | 109,240 | $0.99 | $108,147.60 |
DisclosureSEC source: 0001062993-22-013879 · form4.xml · nonDerivative · entry 5 Gillheeney Gary S. · CIK 0001757373 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 507,482 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.